The global organoids and spheroids market was valued at USD 1.86 billion in 2024 and is projected to reach USD 6.27 billion by 2030, expanding at a robust CAGR of 23.2% from 2025 to 2030. One of the major factors supporting market growth is the increasing use of organoid models to study how the COVID-19 virus impacts multiple intestinal cell types, reinforcing the relevance of organoids in advanced biomedical research.
Organoids and spheroids are increasingly being adopted as reliable in vitro models for drug screening, toxicity testing, and disease modeling. Scientists are actively leveraging these systems to identify and validate promising drug candidates, accelerating the pace of pharmaceutical research while improving predictive accuracy compared to traditional 2D cell cultures.
Research institutions and biotechnology companies are intensifying efforts to develop organoid models that closely replicate complex human diseases, including colon cancer, lung cancer, chronic kidney disease, and various genetic disorders. These miniature, three-dimensional structures enable researchers to observe disease progression and treatment responses in a more physiologically relevant environment.
As of February 2024, 106 clinical research studies involving organoids were ongoing, according to ClinicalTrials.gov, highlighting the growing clinical relevance of this technology. In parallel, continuous technological advancements in organoid development—such as improved culturing techniques and enhanced reproducibility—are further strengthening their effectiveness in pharmaceutical research and translational medicine.
Key Market Trends & Insights
- North America dominated the organoids and spheroids market with a 34.72% revenue share in 2024
- The U.S. accounted for the largest share of market revenue within North America in 2024
- By type, the organoids segment led the market with a 59.65% revenue share in 2024
- By application, developmental biology held the largest share at 30.17% in 2024
Download a free sample PDF of the Nail Salon Market Intelligence Study by Grand View Research.
Market Size & Forecast
- 2024 Market Size: USD 1.86 Billion
- 2030 Projected Market Size: USD 6.27 Billion
- CAGR (2025–2030): 23.2%
- North America: Largest market in 2024
Competitive Landscape
The organoids and spheroids market is characterized by strategic partnerships and distribution agreements aimed at expanding therapeutic applications and advancing 3D cell culture technologies.
In March 2024, CHA Biotech entered into a CDMO agreement with Cell in Cells, a regenerative medicine firm focused on cell-based therapies. The collaboration aims to develop and manufacture organoid-based treatments for cartilage diseases, supporting innovation in regenerative medicine.
Earlier, in August 2023, InSphero signed a distribution agreement with Advanced BioMatrix to broaden the adoption of 3D cell culture technologies. This partnership supports the transition from conventional suspension-based cultures to scaffold-based organoid and spheroid models, enabling more complex tissue modeling.
Key Players Include
- 3D Biomatrix
- 3D Biotek LLC
- AMS Biotechnology (Europe) Limited
- Cellesce Ltd.
- Corning Incorporated
- Greiner Bio-One
- Hubrecht Organoid Technology (HUB)
- InSphero
- Lonza
Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.
Conclusion
The organoids and spheroids market is undergoing rapid expansion, driven by increasing adoption in drug discovery, disease modeling, and regenerative medicine research. Strong growth in North America, rising clinical research activity, and continuous advancements in organoid engineering are reinforcing the market’s upward trajectory. As pharmaceutical and biotechnology companies seek more predictive, human-relevant research models, organoids and spheroids are expected to play an increasingly critical role in shaping the future of biomedical research and therapeutic development through 2030.
No comments:
Post a Comment